Loading…
Employees: 334
Size Livsmed (491000.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $706M, the 284th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩37,950 on 6 Nov 2026.
Performance Over six months the shares fell 46.7%, against -6.1% for the median peer and -24.5% for the South Korea market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 88.8% over the last twelve months (peer median +5.9%); the operating margin is -58.9% (peer median 13.7%).
Valuation It trades at 17.2× enterprise value to sales against a peer median of 3.3× (most expensive of 21).
Capital Return on invested capital runs 25.7 points below its cost of capital (5.4% WACC).
Next results Next results expected around 2 Dec 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩52.8B | ₩51.2B | ₩27.1B | ₩17.3B | ₩9.68B |
| Revenue growth | — | +89% | +57% | +78% | — |
| Gross profit | ₩25.5B | ₩28.8B | ₩13.9B | ₩8.97B | ₩5.08B |
| EBITDA | -₩27.3B | -₩19.9B | -₩24.9B | -₩22.9B | -₩16.4B |
| Net income | -₩26.5B | -₩22.9B | -₩25.6B | -₩57.0B | -₩59.0B |
| Free cash flow | n/a | -₩42.0B | -₩32.0B | -₩27.0B | -₩18.5B |
| Capital expenditure | n/a | ₩7.72B | ₩5.61B | ₩2.49B | ₩965M |
| Total debt | ₩13.6B | ₩11.6B | ₩8.48B | ₩33.4B | ₩30.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 491000.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.8% | -1.4% | 11th highest of 21 |
| 6-month return | -46.7% | -6.1% | lowest of 21 |
| Distance from 52-week high | -60.4% | -20.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +88.8% | +5.9% | highest of 21 |
| Operating margin | -58.9% | 13.7% | 2nd lowest of 21 |
| EV / Sales | 17.2× | 3.3× | most expensive of 21 |
| ROIC minus cost of capital | -25.7 pp | +4.1 pp | 3rd lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | 17.2× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | 7.6× | n/a | n/a |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 7.2× | 29.1% | +6.8% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 3.0× | 0.1% | +40.3% |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 4.2× | 8.1% | -1.9% |
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 3.4× | 21.1% | +13.2% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 3.7× | 16.7% | +25.9% |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 1.6× | -9.7% | +2.9% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 1.6× | 11.1% | +14.2% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $684M | -21% | -13% | 31% | 2.6× | -5.4% | +2.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 3.8× | n/a | n/a |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 1.4× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 2.8× | -2.1% | +11.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 3.3× | 13.5% | +13.3% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 2.2× | -11.4% | +6.7% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | 11.1× | 33.5% | -0.6% |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 3.3× | -2.4% | +15.7% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | 2.6× | n/a | n/a |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 0.7× | -10.5% | +12.4% |
| Cowealth Medical China 603122.SS | China | $648M | -28% | -18% | -5% | 6.8× | n/a | n/a |
| SunMax Biotechnology 4728.TWO | Taiwan | $643M | +1% | +12% | 50% | 9.4× | -0.7% | +18.8% |